0002) compared to mono-infected patients in the DAA era. However, more HCV/HIV coinfected patients were engaged in care (93% vs. HCV mono-infected and HCV/HIV coinfected patients had similar treatment (6% vs. All patients had 88% engagement in primary care during 2008–2013. Data were analyzed on a modified HCV Continuum of Care based on these stages: HCV diagnosis, engagement in medical care, HCV treatment, and HCV sustained virologic response (SVR) for differences between HCV/HIV coinfected and HCV mono-infected patients. A review of summary data from our local HCV Clinical Case Registry was conducted for the interferon treatment era (2008–2013) and the DAA era (2014–2015). We compared the continua of care between our HCV/HIV coinfected and HCV mono-infected patients during 2008– 2015. Treatment of chronic hepatitis C virus (HCV) infection included use of pegylated interferon-based regimens before 2014 and direct-acting agents (DAA) since 2014 at the VA Medical Center in Washington, DC.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |